TY - GEN
T1 - Probabilistic and Dynamic Molecule-Disease Interaction Modeling for Drug Discovery
AU - Fu, Tianfan
AU - Xiao, Cao
AU - Qian, Cheng
AU - Glass, Lucas M.
AU - Sun, Jimeng
N1 - Funding Information:
This work was supported by NSF award SCH-2014438, PPoSS 2028839, IIS-1838042, NIH award R01 1R01NS107291-01 and OSF Healthcare.
Publisher Copyright:
© 2021 Owner/Author.
PY - 2021/8/14
Y1 - 2021/8/14
N2 - Drug discovery aims at finding promising drug molecules for treating target diseases. Existing computational drug discovery methods mainly depend on molecule databases, ignoring valuable data collected from clinical trials. In this work, we propose PRIME to leverage high-quality drug molecules and drug-disease relations in historical clinical trials to narrow down the molecular search space in drug discovery. PRIME also introduces time dependency constraints to model evolving drug-disease relations using a probabilistic deep learning model that can quantify model uncertainty. We evaluated PRIME against leading models on both de novo design and drug repurposing tasks. Results show that compared with the best baselines, PRIME achieves 25.9% relative improvement (i.e., reduction) in average hit-ranking on drug repurposing and 47.6% relative improvement in success rate on de novo design.
AB - Drug discovery aims at finding promising drug molecules for treating target diseases. Existing computational drug discovery methods mainly depend on molecule databases, ignoring valuable data collected from clinical trials. In this work, we propose PRIME to leverage high-quality drug molecules and drug-disease relations in historical clinical trials to narrow down the molecular search space in drug discovery. PRIME also introduces time dependency constraints to model evolving drug-disease relations using a probabilistic deep learning model that can quantify model uncertainty. We evaluated PRIME against leading models on both de novo design and drug repurposing tasks. Results show that compared with the best baselines, PRIME achieves 25.9% relative improvement (i.e., reduction) in average hit-ranking on drug repurposing and 47.6% relative improvement in success rate on de novo design.
KW - drug discovery
KW - probabilistic deep learning
UR - http://www.scopus.com/inward/record.url?scp=85114906585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114906585&partnerID=8YFLogxK
U2 - 10.1145/3447548.3467286
DO - 10.1145/3447548.3467286
M3 - Conference contribution
AN - SCOPUS:85114906585
T3 - Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining
SP - 404
EP - 414
BT - KDD 2021 - Proceedings of the 27th ACM SIGKDD Conference on Knowledge Discovery and Data Mining
PB - Association for Computing Machinery
T2 - 27th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, KDD 2021
Y2 - 14 August 2021 through 18 August 2021
ER -